A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status
Authors:
Open Access
- 2 March 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (1) , 135-145
Abstract
Aims: Guidance on clozapine dosing in treatment‐resistant schizophrenia is based largely on data from White young adult males. This study aimed to investigate the pharmacokinetic profiles of clozapine and N‐desmethylclozapine (norclozapine) across the age range, accounting for sex, ethnicity, smoking status and body weight.Methods: A population pharmacokinetic model, implemented in Monolix, that linked plasma clozapine and norclozapine via a metabolic rate constant, was used to analyse data from a clozapine therapeutic drug monitoring service, 1993–2017.Results: There were 17 787 measurements from 5960 patients (4315 male) aged 18–86 years. The estimated clozapine plasma clearance was reduced from 20.2 to 12.0 L h−1 between 20 and 80 years. Model‐based dose predictions to attain a predose plasma clozapine concentration of 0.35 mg L−1 was 275 (90% prediction interval 125, 625) mg day−1 in nonsmoking, White males weighing 70 kg and aged 40 years. The corresponding predicted dose was increased by 30% in smokers, decreased by 18% in females, and was 10% higher and 14% lower in otherwise analogous Afro‐Caribbean and Asian patients, respectively. Overall, the predicted dose decreased by 56% between 20 and 80 years.Conclusion: The large sample size and wide age range of the patients studied allowed precise estimation of dose requirements to attain predose clozapine concentration of 0.35 mg L−1. The analysis was, however, limited by the absence of data on clinical outcome and future studies are required to determine optimal predose concentrations specifically in those aged over 65 years.Keywords
Funding Information
- UCLH Biomedical Research Centre
This publication has 31 references indexed in Scilit:
- Drug Metabolism in Older People--A Key Consideration in Achieving Optimal Outcomes With MedicinesThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Aging, Drugs, and Drug MetabolismThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Genetic variation in CYP3A43 explains racial difference in olanzapine clearanceMolecular Psychiatry, 2011
- Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007Therapeutic Drug Monitoring, 2010
- The safety of clozapine in the elderlyExpert Opinion on Drug Safety, 2008
- Sex, Race, and Smoking Impact Olanzapine ExposureThe Journal of Clinical Pharmacology, 2008
- Plasma clozapine concentration coefficients of variation in a long-term studySchizophrenia Research, 2005
- Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine ConcentrationsJournal of Clinical Psychopharmacology, 2004
- Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's DiseaseNew England Journal of Medicine, 1999
- Convergence of a stochastic approximation version of the EM algorithmThe Annals of Statistics, 1999